[Osteoporosis and bisphosphonates].
Zuber
M A
MA
Klinik für Rheumatologie der Universität Magdeburg, Fachkrankenhaus Vogelsang, Sophie-von-Bötticher-Strasse 1, 39245, Gommern, Germany. MAZuber@web.de
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000139:chemically induced*; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate